Irinotecan, an antitumor enzyme inhibitor mainly used for the treatment of colorectal cancer [41], is suitable for the her2-enriched subtype, which mediates the specific crosstalk among the risk pathways of the her2-enriched subtype through regulating hsa-miR-23a and hsa-miR-324. The gene discussed is ERBB2; the disease is colorectal cancer.